Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...
Booking Health, a global medical travel platform, announced the expansion of patient access to dendritic cell immunotherapy for recurrent glioblastoma, f...
-Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Best-in-Class PTRS, announced results from the landmark myCare-040 clinical ...
Corner Therapeutics, an in vivo T cell modulation and immunotherapy company pioneering novel approaches to cancer and infection, published research in mB...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA ...
World’s #1 Selling Contact Lens Brand ACUVUE® brings pioneering innovation for astigmatic patients, providing visual clarity and comfort Johns...
Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 2...
Science 37, the leader in expanding patient access to clinical trials, and Catalent®, a global leader in enabling pharma, biotech, and consumer healt...
Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered...
Gilead Sciences celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the co...
Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs Amgen announced plans to invest more than ...
According to recent statistics, the WHO (World Health Organization) has conducted an assessment of mpox cases in Africa, which showed that, as of 2...
New Jersey at a Glance – Often dubbed the “Medicine Chest of the World,” New Jersey has a rich legacy and a dynamic present as a global h...
Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clin...
© 2025 Biopharma Boardroom. All Rights Reserved.
